Latest / The Best of the Money Show / Dis-Chem revenue hits R23bn, but earnings fall
Transcript
- 0:00Speaker 1: Diskem reporting today, its headline earnings per share down nearly 13%
- 0:03Speaker 1: for the six months to the end of August, mainly,
- 0:06Speaker 1: I suppose, because of the steep investment in its innovation hub,
- 0:09Speaker 1: X Bigly Labs. Its revenue, though, up by a very
- 0:12Speaker 1: strong 8%. Its front shop volume growth up 5.5%, much
- 0:17Speaker 1: stronger than competitors in the industry. The CEO at Diskem
- 0:20Speaker 1: is Roy Marais. Roy, good evening. Thanks for the time.
- 0:23Speaker 1: Really do appreciate it. Your headline earnings are lower. It's
- 0:26Speaker 1: really because of the big investment in X Bigly Labs.
- 0:29Speaker 1: Are you convinced that that's going to pay off? It's
- 0:31Speaker 1: had a material impact on your earnings.
- 0:35Speaker 2: Evening, Stephen. So, it has. I think what X Bigly
- 0:39Speaker 2: Labs represent is a different approach to kind of data-led
- 0:43Speaker 2: retailing decision-making in South Africa, you know, with the ambition
- 0:47Speaker 2: to kind of do true omni-channel retailing. And the first
- 0:50Speaker 2: signs of it, I mean, Better Rewards, which is a
- 0:52Speaker 2: program that drove the top-line growth, has been really positive. So,
- 0:55Speaker 2: I mean, internally, very convinced of the trajectory of the
- 0:58Speaker 2: group and the investment that we've made in Big E.
- 1:00Speaker 1: I mean, your Better Rewards program, members of that are
- 1:03Speaker 1: now 86% of your sales. It's a big number. It's
- 1:06Speaker 1: a race of rewards programs in a way. Do you
- 1:09Speaker 1: believe you're winning that race?
- 1:13Speaker 2: Yeah, I mean, look, it's early on. I think there
- 1:17Speaker 2: was a lot of planning and design methodology in the
- 1:19Speaker 2: way that we shaped up the Better Rewards Program. We
- 1:23Speaker 2: see the Rewards Program as a health funding solution, and
- 1:26Speaker 2: the idea is to open up more value in the
- 1:28Speaker 2: consumer's wallet, in South African consumer's wallet, to allow them
- 1:31Speaker 2: to invest in their health care. Of course, we always
- 1:34Speaker 2: expected that competitors would you know, would replicate or chase
- 1:38Speaker 2: the program down. And our job is to continue to
- 1:40Speaker 2: evolve it and create value. I think the consumer is
- 1:43Speaker 2: so constrained and better rewards and the success of the
- 1:46Speaker 2: program is an example of where you get it right.
- 1:48Speaker 2: You do trap and access the consumer better than your competitors. So, yeah,
- 1:54Speaker 2: very positive early sign from the program.
- 1:57Speaker 1: How long do you think you'll have to keep investing
- 1:59Speaker 1: at this level? I know you've been, you know, employing
- 2:01Speaker 1: people and actuaries and data scientists are probably not that cheap.
- 2:05Speaker 1: Once you've employed them, you have to keep them. But
- 2:08Speaker 1: do you expect those costs to start coming down soon?
- 2:12Speaker 2: So, I mean, the investment in the cost remains. I
- 2:15Speaker 2: think what will come down is obviously, you know, the
- 2:17Speaker 2: first half in the prior year. So our comparative period
- 2:19Speaker 2: didn't have that level of investment and hence the impact
- 2:23Speaker 2: on HEPs. I mean, we anticipate a much stronger second
- 2:26Speaker 2: half and a good an actual good full year result. So, yeah.
- 2:30Speaker 2: The investment has been made. We don't anticipate our operating
- 2:34Speaker 2: margins to fall below the levels that they are, and
- 2:37Speaker 2: it's an opportunity for us now with the second half
- 2:40Speaker 2: to start rebuilding that operating margin, but really taking the
- 2:43Speaker 2: benefit of what is a modern, reorganized infrastructure to adapt
- 2:47Speaker 2: to a consumer in South Africa that, like I said,
- 2:49Speaker 2: is very value conscious.
- 2:51Speaker 1: You've been able to significantly improve your revenues. I mean,
- 2:54Speaker 1: they're up 8%, and when you consider the size of
- 2:57Speaker 1: your operation and the sort of general... feeling of what
- 3:00Speaker 1: the world is like at the moment. You must be
- 3:02Speaker 1: quite chuffed with that.
- 3:05Speaker 2: I mean, to me, that is the real proof point
- 3:09Speaker 2: of a change in the way of working, you know,
- 3:11Speaker 2: the investment we've made in Bigly. I think the 8%
- 3:15Speaker 2: is a good number, but more importantly, you know, as
- 3:17Speaker 2: we described it, I mean, we've got volume gains of 5.5%
- 3:20Speaker 2: against the market that over the last 12 months has
- 3:24Speaker 2: been flat, you know, and that's really positive. It means
- 3:28Speaker 2: more consumers are accessing our channel, more brand credibility with consumers,
- 3:33Speaker 2: consumers almost not necessarily shopping between retailers, but believing that
- 3:38Speaker 2: we have the always-on best price in the market, and
- 3:40Speaker 2: that's always been the design of the program.
- 3:44Speaker 1: I mean, you're still investing in new stores. You're changing
- 3:47Speaker 1: the design of some of them. How important is the
- 3:49Speaker 1: design of a store to get people in and keep
- 3:51Speaker 1: them in, or more importantly, to get them coming back?
- 3:56Speaker 2: So the design of the store and the process that, again,
- 3:58Speaker 2: was X Biggie Labs was very much a purposeful process.
- 4:03Speaker 2: So it's not just a reimagination of what the brand
- 4:06Speaker 2: can look like in a space. It's actually looking at
- 4:08Speaker 2: the space and saying, how does the space unlock a
- 4:11Speaker 2: different way of operating? The best example of that is
- 4:14Speaker 2: in our store, the future formats, the way that you
- 4:16Speaker 2: engage in the dispensary is very different. It's been designed
- 4:18Speaker 2: in a way that means you can reduce the time
- 4:21Speaker 2: that a consumer takes to get a script. If you
- 4:23Speaker 2: can do that, you can reduce the cost. which obviously
- 4:26Speaker 2: is burning and haunting, but allows you to pass back
- 4:28Speaker 2: value to the consumer. So the way we've approached space
- 4:32Speaker 2: has been very strategic. And the new format is just
- 4:35Speaker 2: not a better looking version of the brand. It also
- 4:38Speaker 2: allows us to do some of our strategic things better.
- 4:41Speaker 1: It seems that one of the elements of this, one
- 4:43Speaker 1: of the things that helped you to raise your revenue,
- 4:45Speaker 1: was that you've made quite a bit of money from
- 4:48Speaker 1: selling GLP-1 weight loss drugs. They are very expensive. There
- 4:52Speaker 1: will be generics. There'll be other brands coming soon. You
- 4:55Speaker 1: could sell a lot more of them than I imagine.
- 4:57Speaker 1: I'm sure you will. But the price will be lower.
- 4:59Speaker 1: How do you see that playing out? I mean, could
- 5:01Speaker 1: they make less of a contribution in the future? Could
- 5:04Speaker 1: the volume actually mean that they make more of a
- 5:06Speaker 1: contribution for you in the future?
- 5:08Speaker 2: I mean, so it's unknown at this stage. I think
- 5:12Speaker 2: the GLP-1 category is... potentially a huge growth opportunity from
- 5:17Speaker 2: a volume perspective. I mean, value is driving the growth
- 5:21Speaker 2: or supportive growth in our dispensary category at the moment.
- 5:24Speaker 2: But to the point that you made, I think the
- 5:26Speaker 2: market is so responsive to a price point or the genericization,
- 5:29Speaker 2: which means you can take those drugs at a lower
- 5:32Speaker 2: price point. Ultimately, my view on the GLP-1 is that
- 5:36Speaker 2: it will be handled and treated like a chronic condition
- 5:39Speaker 2: the price point will come down but there will be
- 5:41Speaker 2: a lot of more volume and it's going to be
- 5:43Speaker 2: interesting to see how that plays out but certainly a
- 5:45Speaker 2: category on an area in the dispensary that is really
- 5:48Speaker 2: growing strongly.
- 5:49Speaker 1: I mean there's so many fakes in the market and
- 5:52Speaker 1: there's a whole complicated story around compound pharmacies as well
- 5:55Speaker 1: does that hurt you the fake products.
- 5:59Speaker 2: I think that's the tension that exists. Obviously, there's a
- 6:03Speaker 2: legitimate market and then the market that you describe. I
- 6:06Speaker 2: think the market that you describe is driven by demand.
- 6:08Speaker 2: And I think genericization as a function of price point
- 6:11Speaker 2: reduction is going to allow the conventional and legal market
- 6:14Speaker 2: to grow. And obviously, the illegitimate market or parts of
- 6:18Speaker 2: the market to reduce. So we see that as an opportunity, genericization, regulation,
- 6:23Speaker 2: especially the point that you made on compounding and how
- 6:26Speaker 2: that's been curbed. you know, that's just more supportive of
- 6:28Speaker 2: a brand that's doing, you know, I suppose selling into
- 6:31Speaker 2: the legitimate part of the market. So that's a positive
- 6:33Speaker 2: for us.
- 6:34Speaker 1: Roy Mirage, really appreciate the time on a Friday night.
- 6:36Speaker 1: Thank you so much. The CEO at Diskem. Well, big
- 6:40Speaker 1: investments in innovation. It's going to be very interesting to
- 6:42Speaker 1: see how it all plays out.